Department of Health Research, Ministry of Health and Family Welfare, Government of India
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार
WHO Collaborating Centre For Research and Training On Diarrhoeal Diseases
Field of Research:
Educational Background:
Master of Science in Physiology from University College of
Science & Technology, Calcutta University,
PhD in Physiology ,ICMR- National institute of Cholera and
Enteric Diseases, Beliaghata, Calcutta, under super guidance of
Dr. G.Balakrish Nair, PhD, FNA, FNASc, FTWAS, FAAM.
1st Post-Doctoral research under Dr Dipak Sarkar, at Dept of
Physiology, Rutgers -The State University of New Jersey, New
Brunswick, USA.
2nd Post-Doctoral research, Harvard Medical School Prof. R K
Goyal, Mallinckrodt Professor of Medicine, renowned
gastroenterologist.
3rd Post-Doctoral research under Dr. Shinji Yamasaki, Graduate
School of Life and Environmental Sciences, Osaka Prefecture
University, 1 Gakuen-cho, Nakaku, Sakai, Osaka Prefecture
University, Osaka, Japan
.
Research Achievement:
Twelve Patents (https://vaccine.icmr.org.in/shigella)
Shigella vaccine
Hilleman Laboratories and ICMR-NICED has tied up to
commercialize Shigella vaccine. After signing of the MoU,
necessary technology transfer was done to initiate the work.
After developing and optimizing the process, MSD Welcome Trust
Hilleman Laboratories will be manufacturing the product on a
non-GMP (i.e. non-Good Manufacturing Practice) level. And thus
NICED continues to work on Shigella Vaccine to make further in
roads towards its unexplored areas. ICMR licensed the technology
further scaling up and commercialisation to Hilleman
Laboratories Pvt. Ltd., meeting at New Delhi on April 23, 2019
at the ICMR Headquarters. BCIL executed the License Agreement
with NICED on behalf of ICMR and Hilleman Labs. Shigella vaccine
candidate has been awarded a research grant by the European and
Developing Countries Clinical Trials Partnership (EDCTP). MSD
Welcome Trust Hilleman Laboratories will be manufacturing the
low cost product, Phase I & II proof-of-concept will be in
Africa in 2023.
Name | Dr. Hemanta Koley |
---|---|
Designation | Scientist F |
Date of joining ICMR | 1st October 2004 |
Date of joining present post | 1st September 2021 |
Discipline | Physiologist |
Division | Bacteriology |
Specialization | Enteric Bacterial Research |
Email : | hemantakoley@hotmail.com |
Academic Qualification | |
Graduation | BSc in Physiology. |
Post Graduation | MSc in Physiology |
Doctoral | Physiology |
Post-Doctoral Research | Pathophysiology |
In 1992, after completion of Master degree in Human
Physiology from Dept. of Physiology, University College
of Science & Technology, University of Calcutta, Hemanta
Koley joined the Division of Bacteriology, ICMR-National
Institute of Cholera and Enteric Diseases (NICED), an
integral Institute of the Indian Council of Medical
Research and a WHO Collaborating Centre for Research and
Training in Diarrhoeal Diseases, Kolkata, India, for Ph.
D. degree under supervision of Dr. GB Nair.
In 1996, he joined as Associate Professor in Dept. of
Physiology, College of Medical Sciences-Nepal, where he
devoted himself entirely in teaching medical students.
Meanwhile, Dr. Koley got an opportunity for
Post-doctoral research in the laboratory of Prof Dipak K
Sarkar, Dept. Animal Sciences, Rutgers -The State
University of New Jersey, New Brunswick, USA. After
completion of one year in Rutgers University, Dr. Koley
moved to Boston, joined Gastroenterology Section of
Harvard Medical School, as Research Associate and worked
there on "Molecular mechanism of Barrett's oesophagus
and to identify therapeutic target for adenocarcinoma"
under leadership of Prof. R K Goyal, renowned
gastroenterologist.
In the year of 2004, 1st October, he came back India and
joined back to Division of Bacteriology, National
Institute of Cholera and Enteric Diseases (NICED),
Kolkata, and has been since devotedly working on
development of a single vaccine against all circulating
enteric organisms.
Laboratory has identified a number of potential vaccine candidates like outer membrane vesicles, Bacterial ghost antigen, Heat killed bacterial antigen, Formalin treated bacterial antigen, Live attenuated bacterial antigen, Nanoparticle formulation specially chitosan-alginate ompA nanoparticle, subunit vaccine
Research multiple projects are focus on the development of novel vaccine candidate for the livestock and human against enteric pathogens like Vibrio cholerae, Shigella, Typhoidal and Non-typhoidal Salmonella, Dirrhoeagenic Escherichia coli( DEC), Campylobacter, and Helicobacter pylori.
Special expertise on outer membrane vesicles based studies on various animal models, like Mouse, Rat, Hamster, Guinea pig, Rabbit, Chicken and Zebra fish.
Long path programme of the laboratory is to develop a
single vaccine candidate against all enteric pathogens.
.
National Membership:
.